Navigation Links
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
Date:7/15/2009

seline in viral load (log10 HIV RNA) at week 48 of treatment. A key secondary efficacy endpoint is the proportion of patients with plasma HIV RNA less than 50 copies/mL at week 48 of treatment.

Atazanavir boosted by ritonavir was selected for use in this study because it is recommended as an option for first-line therapy in both the International AIDS Society and Department of Health and Human Services guidelines for antiretroviral therapy. Additionally, like vicriviroc, it is administered as a once daily dose and it has been shown to have a more favorable lipid safety profile than other drugs in the PI class.

The study is being sponsored by Schering-Plough with support from Bristol-Myers Squibb.

Vicriviroc also is being studied in two large ongoing Phase III clinical studies in treatment-experienced HIV patients. For more information about vicriviroc clinical studies, please visit www.clinicaltrials.gov, search term: vicriviroc.

Key Safety Findings with Vicriviroc

A pooled data analysis was conducted for two vicriviroc Phase II studies involving 205 treatment-experienced HIV-infected patients who continued on vicriviroc at the completion of 48 weeks of treatment in an open-label extension for each study. Patients received vicriviroc for up to 216 weeks of total treatment duration as part of an optimized antiretroviral regimen. AIDS-associated opportunistic infections and conditions were observed infrequently and sporadically. Infections involving the upper and lower respiratory tract were the only other infections or adverse events that occurred in 5 percent or more of patients. Elevations of liver enzymes and bilirubin were noted, but were not characteristic of drug-induced liver injury and were judged to be not related to vicriviroc. These infections and other adverse eve
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
2. Schering-Plough Announces Results of the Early ACS Trial
3. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
4. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
5. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
8. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
9. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
10. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced that the ... Lixte,s lead compound, LB‑100, is being conducted, has been expanded ... Kovach , M.D., the founder and President of Lixte, said ... a single site. Accrual of patients, however, was slower than ...
(Date:1/23/2015)... , Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), ... equipment for all forms of sports, including extreme motor ... brace, announced today that the UISP Lega Motociclismo Lombardia, ... all riders to wear a neck brace during its ...
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... has approved a share repurchase program. The open-ended authorization ... of Mallinckrodt plc ordinary shares. "Funding ... top priorities as we continue to pursue a range ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... Jan. 19, 2012  CutisPharma, Inc. announced the introduction ... Unit-of-Use oral suspension compounding kits. These new kits ... widely used proton pump inhibitors (PPIs). Traditionally, compounded ... to several hours to prepare and are quite ...
... Patients with hip and knee replacements can now ... their body thanks to a new tracking system being ... Sporer and Wayne Paprosky, MOR hip and knee orthopaedic ... all compliant patients with radiostereometric analysis (RSA) beads, which ...
Cached Medicine Technology:CutisPharma Expands Product Line with New Oral Suspension Prescription Compounding Kits 2New Technology to Track Movement and Durability of Implants in Hip and Knee Replacement Patients 2New Technology to Track Movement and Durability of Implants in Hip and Knee Replacement Patients 3
(Date:1/22/2015)... 2015 Gabe’s Chemo Duck Program is pleased to ... app ever created for kids with cancer. The Chemo Duck App, ... is filled with enjoyable games to help children of all ages ... app helps to keep kids entertained, educated and at ease while ...
(Date:1/22/2015)... a famous wedding dress company offering many trendy designs. Today, ... Twitter, and Pinterest. The fans will have an opportunity to ... week. , Moreover, the company has extended its 2015 New ... for more information. , Angelweddingdress is a famous ...
(Date:1/22/2015)... 2015 Juvent Sports ( http://www.juventsports.com ) ... PGA Merchandise Show to bestow a Juvent Sports Achievement ... golfer, Arlene McKitrick. The award commemorated and congratulated McKitrick ... win. She won her first amateur tournament in 1979 ...
(Date:1/22/2015)... over 20 years, Dr. David Cruz of Cruz Chiropractic Care ... just about every type of injury that can result from car ... twenty-plus years, the team at Doctors on Liens has ... doctor. With the combined breadth of experience between the ...
(Date:1/22/2015)... La Jolla, Calif. (PRWEB) January 22, 2015 ... and Assemblymembers Susan Bonilla (D-Concord) and Kristin Olsen ... (CHI) for their leadership in advancing biotechnology, biomedical ... Mitchell, Bonilla and Olsen each received the “2014 ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3
... recommended for breast cancer patients, who show positive for ... is positive, and they have a more resistant and ... women are Her-2/neu positive and the treatment for these ... does not show any significant disease reduction. These patients ...
... common forms of dementia among older people, which initially involves ... memory, and language. // , ,Researchers from USA have ... and have speculated about their use as preventive agents. The ... the RDA (400 ìg/d) is associated with a reduced risk ...
... Lausanne) and the CHUV (Lausanne University Hospital) have discovered ... the true multipotent stem cell category and can // ... and follicle replacement. , ,The research team has ... the October 3 issue of Proceedings of the National ...
... India has always been looked at by outsiders as the ... harmonious central key to getting in touch with the spiritual ... large sub-continent then what meets the eye at first glance ... ,Tourism has been a thriving business in India for ...
... for a long and healthy life has been known for ... can cause dangerous interactions when taken along with medicines. Foods ... orally administered drugs. The effect does not hold good for ... or well documented of these effects is the one involving ...
... that 36 million deaths occurs world wide due to chronic ... serious measures has to be taken to prevent this // ... responsible for the cause of the diseases is Tobacco, poor ... fats and sugars, doing less activity due to work and ...
Cached Medicine News:
The Mitek Restore System, designed in conjunction with Sanford S. Kunkel, M.D., offers instrumentation for all ACL Procedures....
The cordless Simon Dermatome with rechargeable battery is used to harvest split-thickness skin grafts and for debridement....
... quality and innovation has resulted in one ... Model C is an air dermatome especially ... in burn care surgery. The Model C ... same dedication to quality, durability and reliability ...
Needle holder, delicate, curved without lock...
Medicine Products: